AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

• Status: Not yet recruiting
• Trial end date: 2025-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase I/II clinical trial evaluating the association of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma.

The primary objectives of this study were to determine the recommended dose of AGuIX in combination with radiotherapy and TMZ during the concomitant radiochemotherapy period (phase I) and to estimate the efficacy of the combination radiochemotherapy + AGuIX (recommended dose), measured by the 6-month progression-free survival rate (PFS) (phase II)

Three dose levels of intravenous AGuIX nanoparticles will be explored: 50 mg/kg, 75 mg/kg and 100 mg/kg.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Jean Perrin
• Collaborator: French Ministry of Health (PHRCI-19-060)
• Treatments: Temozolomide

Criteria

Inclusion Criteria:

• Histological diagnosis of grade IV glioblastoma (biopsy or partial surgery)

• Patient not operated or partial resection

• KPS ≥ 70%

• Age ≥ 18 years old and <75 years old

• Life expectancy ≥ 6 months

• Platelets ≥ 100,000 / mm3

• PNN ≥ 2000 / mm3

• Hb ≥ 10 g / dL

• Creatinine <1.5 times the upper normal limit or clearance according to Cockcroft-Gault ≥ 50 mL / min

• Liver function (GGT, PAL, ASAT, ALAT, bilirubin) <1.5 times the upper normal limit

• For patients receiving treatment with corticosteroids, treatment with corticosteroids must be at a stable or decreasing dose for at least 14 days before inclusion

• Patient able to swallow and retain oral medication

• Negative serum pregnancy test within 7 days before the first administration of treatment for women

• Women of childbearing potential and men whose partners are of childbearing potential must agree to use, themselves or their partners, an approved method of contraception throughout the treatment and at least 6 months after the last administration of study treatment.

• Obtaining signed informed consent from the patient

• Patient affiliated to a social security regimen

Exclusion Criteria:

• prior brain radiotherapy

• prior chemotherapy (including implants containing carmustine (Gliadel®) or immunotherapy (vaccination included)

• Any contraindication to TMZ listed in the SPCs

• History of major intestinal resection which may modify the absorption of oral drugs according to the judgment of the investigator

• Diagnosed inflammatory bowel disease (Crohn's disease or ulcerative colitis)

• Diarrhea ≥ grade 2 CTCAE (whatever the cause)

• Current or recent treatment with another investigational drug or participation in another therapeutic clinical trial (within 30 days of inclusion).

• History of other cancer in the 5 years preceding inclusion, except for basal cell carcinomas of the skin and in situ carcinomas of the cervix

• Pregnant or breastfeeding women

• Contraindication to MRI or gadolinium injection

• History of severe anaphylactic reactions due to the injection of gadolinium-based contrast product (dotarem, etc.)

• Patient under guardianship or curatorship

• History of nephropathy

• Psychological disorder or social or geographic reasons that may compromise medical monitoring of the trial or compliance with treatment